Logo image of MTSR

METSERA INC (MTSR) Stock Fundamental Analysis

NASDAQ:MTSR - Nasdaq - US59267L1070 - Common Stock - Currency: USD

28.45  -0.14 (-0.49%)

After market: 28.03 -0.42 (-1.48%)

Fundamental Rating

2

MTSR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. MTSR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MTSR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MTSR had negative earnings in the past year.
MTSR Yearly Net Income VS EBIT VS OCF VS FCFMTSR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

MTSR's Return On Assets of -30.28% is fine compared to the rest of the industry. MTSR outperforms 65.59% of its industry peers.
The Return On Equity of MTSR (-41.38%) is better than 69.73% of its industry peers.
Industry RankSector Rank
ROA -30.28%
ROE -41.38%
ROIC N/A
ROA(3y)-26.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTSR Yearly ROA, ROE, ROICMTSR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 50 -50

1.3 Margins

MTSR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTSR Yearly Profit, Operating, Gross MarginsMTSR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

MTSR has about the same amout of shares outstanding than it did 1 year ago.
MTSR has a worse debt/assets ratio than last year.
MTSR Yearly Shares OutstandingMTSR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M 80M 100M
MTSR Yearly Total Debt VS Total AssetsMTSR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 8.85 indicates that MTSR is not in any danger for bankruptcy at the moment.
MTSR has a better Altman-Z score (8.85) than 84.86% of its industry peers.
MTSR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
MTSR has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 8.85
ROIC/WACCN/A
WACCN/A
MTSR Yearly LT Debt VS Equity VS FCFMTSR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 6.55 indicates that MTSR has no problem at all paying its short term obligations.
MTSR's Current ratio of 6.55 is fine compared to the rest of the industry. MTSR outperforms 63.96% of its industry peers.
MTSR has a Quick Ratio of 6.55. This indicates that MTSR is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.55, MTSR is doing good in the industry, outperforming 64.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.55
Quick Ratio 6.55
MTSR Yearly Current Assets VS Current LiabilitesMTSR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

MTSR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -342.97%.
EPS 1Y (TTM)-342.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -9.31% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.81%
EPS Next 2Y-2.77%
EPS Next 3Y-9.31%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTSR Yearly EPS VS EstimatesMTSR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MTSR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTSR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTSR Price Earnings VS Forward Price EarningsMTSR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTSR Per share dataMTSR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as MTSR's earnings are expected to decrease with -9.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.77%
EPS Next 3Y-9.31%

More info and screens

0

5. Dividend

5.1 Amount

MTSR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

METSERA INC

NASDAQ:MTSR (6/30/2025, 8:00:01 PM)

After market: 28.03 -0.42 (-1.48%)

28.45

-0.14 (-0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)N/A N/A
Inst Owners77.6%
Inst Owner ChangeN/A
Ins Owners0.91%
Ins Owner Change11.92%
Market Cap2.99B
Analysts86.67
Price Target51 (79.26%)
Short Float %9.94%
Short Ratio8.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-175.09%
Min EPS beat(2)-331.37%
Max EPS beat(2)-18.8%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.38%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.81%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.91
P/tB 7.25
EV/EBITDA N/A
EPS(TTM)-2.03
EYN/A
EPS(NY)-3.45
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS4.81
TBVpS3.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.28%
ROE -41.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.55
Quick Ratio 6.55
Altman-Z 8.85
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-342.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-2.81%
EPS Next 2Y-2.77%
EPS Next 3Y-9.31%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-571.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-130.6%
EBIT Next 3Y-53.78%
EBIT Next 5YN/A
FCF growth 1Y-182.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-182.65%
OCF growth 3YN/A
OCF growth 5YN/A